Novel Biomarkers for Predicting Preeclampsia

Trends in Cardiovascular Medicine

Volumn 18, Issue 5, 2008, Pages 186-194

  Carty, David M ^a   Delles, Christian ^a   Dominiczak, Anna F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; APOLIPOPROTEIN E; BIOLOGICAL MARKER; ENDOGLIN; INHIBIN A; INSULIN; PLACENTAL GROWTH FACTOR; PLACENTAL PROTEIN 13; PROTEIN A; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

GENOMICS; INSULIN RESISTANCE; MEDICAL RESEARCH; METABOLOMICS; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

ACTIVINS; ANGIOGENESIS INDUCING AGENTS; ANTIGENS, CD; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; FEMALE; HUMANS; INHIBINS; INSULIN RESISTANCE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 51249096279     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2008.07.002     Document Type: Review

References (79)

1. Aquilina J., Barnett A., Thompson O., and Harrington K. Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia. Am J Obstet Gynecol 181 (1999) 131-136
2. Belo L., Gaffney D., Caslake M., et al. Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 112 (2004) 9-15
3. Bersinger N.A., Smarason A.K., Muttukrishna S., et al. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein a (PAPP-A), inhibin A, activin A, and soluble E-selectin. Hypertens Pregnancy 22 (2003) 45-55
4. Brindle J.T., Antti H., Holmes E., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics. Nature Med 8 (2002) 1439-1444
5. Brindle J.T., Nicholson J.K., Schofield P.M., et al. Application of chemometrics to H-1 NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128 (2003) 32-36
6. Burger O., Pick E., Zwickel J., et al. Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 25 (2004) 608-622
7. Butte N.F. Carbohydrate and lipid metabolism in pregnancy: Normal compared with gestational diabetes mellitus. Am J Clin Nutr 71 (2000) 1256S-1261S
8. Canini S., Prefumo F., Pastorino D., et al. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertil and Steril 89 (2008) 174-178
9. Carlsen S.M., Romundstad P., and Jacobsen G. Early second-trimester maternal hyperandrogenemia and subsequent preeclampsia: A prospective study. Acta Obstet Gynecol Scand 84 (2005) 117-121
10. Chafetz I., Kuhnreich I., Sammar M., et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 197 (2007) 35.e1-35.e7
11. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia-Young Investigator Award. Am J Obstet Gynecol 190 (2004) 1541-1547
12. Conde-Agudelo A., Villar J., and Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 104 (2004) 1367-1391
13. Cooper J.C., Sharkey A.M., Charnock-Jones D.S., et al. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 103 (1996) 1191-1196
14. D'Anna R., Baviera G., Corrado F., et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. Br J Obstet Gynaecol 113 (2006) 1264-1269
15. D'Anna R., Baviera G., Corrado F., et al. Is mid-trimester maternal serum inhibin-A a marker of preeclampsia or intrauterine growth restriction?. Acta Obstet Gynecol Scand 81 (2002) 540-543
16. Davidson E.J., Riley S.C., Roberts S.A., et al. Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of pre-eclampsia. Br J Obstet Gynaecol 110 (2003) 46-52
17. Davison J.M., Homuth V., Jeyabalan A., et al. New aspects in the pathophysiology of Preeclampsia. J Am Soc Nephrol 15 (2004) 2440-2448
18. Daviss B. Growing pains for metabolomics. Scientist 19 (2005) 25-28
19. Duley L., Henderson-Smart D.J., Meher S., and King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications (Review). Cochrane Database Syst Rev (2004) CD004659
20. Fasshauer M., Waldeyer T., Seeger J., et al. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. Eur J Endocrinol 158 (2008) 197-201
21. Florio P., Reis F.M., Pezzani I., et al. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 21 (2003) 165-169
22. Francoual J., Audibert F., Trioche P., et al. Is a polymorphism of the apolipoprotein E gene associated with preeclampsia?. Hypertens Pregnancy 21 (2002) 127-133
23. GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet 77 (2005) 127-131
24. Gonzalez-Buitrago J.M., Ferreira L., and Lorenzo I. Urinary proteomics. Clinica Chim Acta 375 (2007) 49-56
25. Han X.L., Holtzman D.M., Mckeel D.W., et al. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82 (2002) 809-818
26. Hofmeyr G.J., Atallah A.N., and Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev (2006) CD001059
27. Hughes G., Bischof P., Wilson G., and Klopper A. Assay of a placental protein to determine fetal risk. BMJ 280 (1980) 671-673
28. Kenny L.C., Dunn W.B., Ellis D.I., et al. Novel biomarkers for preeclampsia detected using metabolomics and machine learning. Metabolomics 1 (2005) 227-234
29. Kenyon G.L., DeMarini D.M., Fuchs E., et al. Defining the mandate of proteomics in the post-genomics era: Workshop report. Mol Cell Proteomics 1 (2002) 763-780
30. Kim S.Y., Ryu H.M., Yang J.H., et al. Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia. J Korean Med Sci 21 (2006) 452-456
31. Kim S.Y., Ryu H.M., Yang J.H., et al. Increased sFLT-1 to PIGF ratio in women who subsequently develop preclampsia. J Korean Med Sci 22 (2007) 873-877
32. Koga K., Osuga Y., Yoshino O., et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88 (2003) 2348-2351
33. Laursen L.S., Overgaard M.T., Soe R., et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 504 (2001) 36-40
34. Lee E.S., Oh M.J., Jung J.W., et al. The levels of circulating vascular endothelial growth factor and soluble FLT-1 in pregnancies complicated by preeclampsia. J Korean Med Sci 22 (2007) 94-98
35. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
36. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
37. Luft F.C. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFLT) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 21 (2006) 3052-3054
38. Luisi S., Florio P., Reis F.M., and Petraglia F. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum Reprod Update 11 (2005) 123-135
39. Makkonen N., Heinonen S., Hiltunen M., et al. Apolipoprotein E alleles in women with pre-eclampsia. J Clin Pathol 54 (2001) 652-654
40. Masuyama H., Nakatsukasa H., Takamoto N., and Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 92 (2007) 2672-2679
41. Masuyama H., Suwaki N., Nakatsukasa H., et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 194 (2006) 551-556
42. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 111 (2003) 649-658
43. Meads C.A., Cnossen J.S., Meher S., et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 12 (2008) 1-270
44. Kronborg C.S., Allen J., Vittinghus E., and Knudsen U.B. Pre-symptomatic increase in urine-orosomucoid excretion in pre-eclamptic women. Acta Obstet Gynecol Scand 86 (2007) 930-937
45. Muttukrishna S., Hyett J., Paine M., et al. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol (Oxf) 64 (2006) 469-473
46. Muttukrishna S., Knight P.G., Groome N.P., et al. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 349 (1997) 1285-1288
47. Muttukrishna S., North R.A., Morris J., et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 15 (2000) 1640-1645
48. Nagy B., Rigo J., Fintor L., et al. Apolipoprotein E alleles in women with severe pre-eclampsia. J Clin Pathol 51 (1998) 324-325
49. NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature 447 (2007) 655-660
50. Nicolaides K.H., Bindra R., Turan O.M., et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 27 (2006) 13-17
51. Ong S., Lash G., and Baker P.N. Angiogenesis and placental growth in normal and compromised pregnancies. Best Pract Res Clin Obstet Gynaecol 14 (2000) 969-980
52. Ong C.Y., Liao A.W., Spencer K., et al. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. Brit J Obstet Gynaecol 107 (2000) 1265-1270
53. Ostendorf T., De Vriese A.S., and Floege J. Renal side effects of anti-VEGF therapy in man: a new test system. Nephrol Dial Transplant 22 (2007) 2778-2780
54. Poston L., Briley A.L., Seed P.T., et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367 (2006) 1145-1154
55. Qazi U., Lam C., Karumanchi S.A., and Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 35 (2008) 631-634
56. Ramsay J.E., Jamieson N., Greer I.A., and Sattar N. Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 42 (2003) 891-894
57. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50 (2007) 137-142
58. Redman C.W., and Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - A review. Placenta 24 (2003) S21-S27
59. Roes E.M., Gaytant M.A., Thomas C.M., et al. First trimester inhibin-A concentrations and later development of preeclampsia. Acta Obstet Gynecol Scand 83 (2004) 117
60. Saito M., Kimoto M., Araki T., et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol 48 (2005) 865-871
61. Salahuddin S., Lee Y., Vadnais M., et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 197 (2007) 28.e1-28.e6
62. Sattar N., Bendomir A., Berry C., et al. Lipoprotein subfraction concentrations in preeclampsia: Pathogenic parallels to atherosclerosis. Obstet Gynecol 89 (1997) 403-408
63. Sargent I.L., and Smarason A.K. Immunology of pre-eclampsia; current views and hypothesis. In: Kurpisz M., and Fernandez N. (Eds). Immunology of human reproduction (1995), BIOS Scientific Publishers Ltd, Oxford 355-370
64. Sherif K., Kushner H., and Falkner B.E. Sex hormone-binding globulin and insulin resistance in African-American women. Metabolism 47 (1998) 70-74
65. Smith G.C., Stenhouse E.J., Crossley J.A., et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metabol 87 (2002) 1762-1767
66. Sniehotta M., Schiffer E., Zürbig P., et al. CE-a multifunctional application for clinical diagnosis. Electrophoresis 28 (2007) 1407-1417
67. Spencer K., Cowans N.J., and Nicolaides K.H. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 28 (2008) 7-10
68. Spencer K., Yu C.K.H., Rembouskos G., et al. First trimester sex hormone-binding globulin and subsequent development of preeclampsia or other adverse pregnancy outcomes. Hypertens Pregnancy 24 (2005) 303-311
69. Staff A.C., Braekke K., Harsem N.K., et al. Circulating concentrations of sFlt1 (soluble fins-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 122 (2005) 33-39
70. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metabol 89 (2004) 770-775
71. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Med 12 (2006) 642-649
72. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
73. Wittke S., Haubitz M., Walden M., et al. Detection of acute rejection by proteomic analysis of urinary samples in renal transplant recipients. Nephrol Dial Transplant 20 (2005) V158-V159
74. Wolf M., Sandler L., Munoz K., et al. First trimester insulin resistance and subsequent preeclampsia: A prospective study. J Clin Endocrinol Metabol 87 (2002) 1563-1568
75. Wolf M., Shah A., Lam C., et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 193 (2005) 16-22
76. Yaron Y., Heifetz S., Ochshorn Y., et al. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 22 (2002) 778-782
77. Zeeman G.G., Alexander J.M., McIntire D.D., et al. Inhibin-A levels and severity of hypertensive disorders due to pregnancy. Obstet Gynecol 100 (2002) 140-144
78. Zhou H., Pisitkun T., Aponte A., et al. Exosomal fetuin-A identified by proteomics: A novel urinary biomarker for detecting acute kidney injury. Kidney Int 70 (2006) 1847-1857
79. Zimmerli L.U., Schiffer E., Zürbig P., et al. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 7 (2008) 290-298